Table 1.
Patient characteristics of the present study population
| Characteristic | No. of patients (%) |
|---|---|
| Median age, years (range) |
58.6 (23.5–89.2) |
| Median CA-125 level at diagnosis, U/ml (range) |
490.5 (7–33439) |
| Median nadir CA-125 level, U/ml (range) |
10 (4–35) |
| Ethnicity |
|
| White |
316 (77.1) |
| Black |
25 (6.1) |
| Hispanic |
56 (13.7) |
| Other* |
13 (3.2) |
| Histology |
|
| Serous |
317 (77.3) |
| Endometrioid |
42 (10.2) |
| Clear cell |
18 (4.4) |
| Mucinous |
9 (2.2) |
| Transitional |
6 (1.5) |
| Undifferentiated |
9 (2.2) |
| MMMT |
9 (2.2) |
| Grade |
|
| High |
361 (88.0) |
| Low |
49 (12.0) |
| FIGO stage |
|
| I |
42 (10.2) |
| II |
31 (7.6) |
| III |
284 (69.3) |
| IV |
53 (12.9) |
| Residual disease after primary surgery |
|
| Optimal (≤ 1 cm) |
322 |
| Suboptimal (> 1 cm) |
65 |
| Unknown |
23 |
| NACT |
|
| Yes |
46 (11.2) |
| No |
354 (86.3) |
| Unknown | 10 (2.4) |
Note: All data are no. of patients (%) unless noted otherwise.
Abbreviations: MMMT, malignant mixed müllerian tumor; FIGO, International Federation of Gynecology and Obstetrics; NACT, Neoadjuvant chemotherapy.
*5 Chinese, 4 Middle Eastern, 1 Japanese, 1 Korean, and 2 Indian patients.